Wednesday, July 8, 2026

Drug profile · INN

diethylcarbamazine citrate

diethylcarbamazine citrate (HETRAZAN) is a nematode gaba-a receptor positive modulator. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — diethylcarbamazine citrate
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

diethylcarbamazine citrate (HETRAZAN) is a nematode gaba-a receptor positive modulator. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN diethylcarbamazine citrate
Brand HETRAZAN
Mechanism Nematode GABA-A receptor positive modulator
Target Nematode GABA-A receptor
Route ORAL
Formulation TABLET

Mechanism of action

Nematode GABA-A receptor positive modulator

Primary target: Nematode GABA-A receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. piperazine citrate Nematode GABA-A receptor positive modulator

Frequently asked questions

What is diethylcarbamazine citrate?

diethylcarbamazine citrate (HETRAZAN) is a nematode gaba-a receptor positive modulator. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for diethylcarbamazine citrate?

HETRAZAN is a marketed brand name for diethylcarbamazine citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of diethylcarbamazine citrate?

diethylcarbamazine citrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.